IFF (NYSE: IFF) reported Q2 EPS of $1.15, $0.03 better than the analyst estimate of $1.12. Revenue for the quarter came in at $2.76 billion versus the consensus estimate of $2.7 billion.

GUIDANCE:

IFF sees FY2025 revenue of $10.6-10.9 billion, versus the consensus of $10.825 billion.

The Company is reiterating its full year 2025 guidance outlined earlier this year, maintaining its outlook for 1% to 4% comparable currency neutral sales growth and 5% to 10% growth in comparable currency neutral adjusted operating EBITDA, despite more challenging market conditions expected in the second half of the year.

Based on recent market foreign exchange rates, the Company now expects that foreign exchange will have an approximately 1% (versus 2% previously) adverse impact to sales growth and an approximately 3% adverse impact to adjusted operating EBITDA growth in 2025.

Full year guidance includes four months of Pharma Solutions results as the divestiture closed on May 1, 2025. This results in an approximately 7% adverse impact to sales growth and an approximately 8% adverse impact to adjusted operating EBITDA growth in 2025.

For earnings history and earnings-related data on IFF (IFF) click here.